Every GLP-1 medication approved to date uses a single mechanism: GLP-1 receptor agonism (semaglutide, liraglutide) or dual GLP-1/GIP agonism (tirzepatide). CagriSema adds a second peptide to the equation — cagrilintide, a long-acting analog of amylin, a pancreatic hormone that reduces appetite through mechanisms distinct from GLP-1. The combination produces weight loss that exceeds either component alone.
How amylin and GLP-1 complement each other
Amylin is co-secreted with insulin from pancreatic beta cells after meals. Its physiological roles include slowing gastric emptying, suppressing post-meal glucagon secretion, and reducing food intake through action on the area postrema in the brainstem. These actions overlap with but are mechanistically distinct from GLP-1's appetite suppression, which works primarily through hypothalamic satiety signaling and vagal nerve pathways.
The complementary mechanisms mean that adding amylin agonism to GLP-1 agonism produces additive appetite suppression without simply doubling the GI side effects — because the two pathways reduce food intake through different neural circuits. This is the biological basis for CagriSema's superior weight loss.
REDEFINE program: the trial architecture
The REDEFINE program consists of multiple Phase 3 trials evaluating CagriSema across different populations:
| Trial | Population | Duration | Key Endpoint |
|---|---|---|---|
| REDEFINE 1 | Adults with obesity (no T2D) | 68 weeks | % body weight change |
| REDEFINE 2 | Adults with obesity + T2D | 68 weeks | % weight change + HbA1c |
| REDEFINE 3 | vs. tirzepatide 15mg | 72 weeks | Superiority in weight loss |
| REDEFINE 4 | Weight maintenance | 68 weeks | Weight regain prevention |
REDEFINE 3 is the commercially critical trial: a head-to-head against tirzepatide 15mg (the current most effective approved medication for weight loss). If CagriSema demonstrates superiority in REDEFINE 3, it becomes the unambiguous best-in-class option — a positioning Novo Nordisk needs to defend its market leadership against Lilly's tirzepatide franchise.
Safety profile
CagriSema's adverse event profile combines the GI effects of both GLP-1 and amylin agonism. Nausea rates are higher than semaglutide alone but comparable to tirzepatide at top doses. The titration schedule is designed to mitigate GI intolerance — slow upward dose adjustment over 16-20 weeks allows GI adaptation before reaching the full therapeutic dose.
Amylin-specific signals include injection site reactions (nodules at the injection site have been reported with pramlintide, the approved amylin analog) and rare episodes of hypoglycemia when used with insulin. In CagriSema trials without concomitant insulin, clinically significant hypoglycemia was rare.
CagriSema represents the first combination peptide approach to reach Phase 3 for obesity. Its ~22-25% weight loss at 68 weeks exceeds every approved monotherapy. The REDEFINE 3 head-to-head vs. tirzepatide will determine whether it's truly best-in-class or just best-in-Novo-Nordisk.
Timeline and market implications
CagriSema has Priority Review status from the FDA. If approved, commercial launch could begin as early as late 2026 or early 2027. Novo Nordisk's manufacturing scale-up — historically a constraint for Wegovy — will be the operational challenge. The company has invested in dedicated production capacity, but meeting anticipated demand for a best-in-class weight loss drug while maintaining Wegovy supply is a non-trivial manufacturing problem.
For patients currently on semaglutide (Wegovy/Ozempic) who have plateaued, CagriSema represents the clearest next-step escalation — same GLP-1 backbone with an additional mechanism. The transition pathway from semaglutide monotherapy to CagriSema is pharmacologically cleaner than switching to tirzepatide (which is a different receptor agonist entirely).